Plain-English translation of NCT07637474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how the immune system's metabolism—the chemical processes that give immune cells energy—affects how well immunotherapy (specifically anti-PD-1/PD-L1 agents) works against lung cancer. They will collect tissue samples from tumors and blood samples from patients to examine immune cells and understand which patients are most likely to benefit from this type of treatment.
Not all patients respond equally well to immunotherapy, and doctors cannot yet predict who will benefit most. This research aims to identify specific metabolic patterns in immune cells that could predict treatment success and potentially help develop better combination therapies.
You likely qualify if…
You likely don't qualify if…
You will provide blood samples and tumor tissue samples (either from surgery or diagnostic biopsy) at specific time points. Depending on which group you join, you may provide samples before treatment starts, before surgery, and during follow-up visits. Researchers will analyze your immune cells and tissue to understand how your body's metabolism responds to immunotherapy treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy
Sponsor
Regina Elena Cancer Institute
Collaborators
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Enrollment target
~150 participants
Started
July 2024
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lorenza Landi, Doctor
IRCCS National Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.